A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
This study is looking into a new medicine called efgartigimod for adults who have a blood condition called primary immune thrombocytopenia (ITP). ITP causes low levels of platelets, which are important for blood clotting. The main goal is to find out how well efgartigimod works (its 'efficacy') and if it's safe to use. You'd first have a check-up period, then be randomly assigned to receive either the study drug (efgartigimod) or a dummy treatment (placebo) for up to 24 weeks. After this, everyone will receive efgartigimod for about two years, followed by a period where no study drug is given. The whole study could last up to 138 weeks.
En un coup d'œil
De quoi parle cette étude ?
This study is designed to learn more about a new treatment, efgartigimod, for adults living with primary immune thrombocytopenia, often just called ITP. ITP is a condition where your body's immune system mistakenly attacks and destroys its own platelets, which are tiny cells in your blood that help it clot. If you don't have enough platelets, you can bruise easily or bleed more than usual.
The researchers want to see if efgartigimod can help increase platelet counts and reduce bleeding in people with ITP. They also want to understand if the medicine is safe and doesn't cause too many side effects. Comparing it to a placebo (a treatment that looks like the real thing but has no active medicine) helps them truly see the effect of efgartigimod.
Participating could mean you receive a new treatment that might help your ITP, or you might receive a placebo at first. After a certain period, everyone in the study will get the active medicine. This type of research is really important because it helps doctors find better ways to manage conditions like ITP and improve the lives of people living with them.
Points clés
- This study is testing a new medicine for adults with ITP.
- It aims to see how well efgartigimod works and if it's safe.
- Participation involves receiving either the study drug or a placebo at first.
- Everyone on the study will get the active medicine eventually.
- The study involves regular clinic visits for IV treatments and check-ups.
- The total study duration could be up to 2.5 years.
Qui peut être éligible ?
To join this study, you need to be at least 18 years old. You must also have had primary ITP for more than a year and have a low platelet count. In the past, you should have tried at least one common ITP treatment (like steroids, IVIg, or other specific medicines) and it didn't work well enough.
There are also some reasons why you might not be able to join. For instance, if you have other serious health problems or a different type of ITP (not primary ITP), or if you have certain related conditions like another serious autoimmune disease or a current severe bleeding problem, you wouldn't be able to take part.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous au moins 18 ans ?
- Have you had primary ITP for more than one year?
- Do you currently have a low platelet count (less than 30)?
- Have you tried at least one previous ITP treatment (like steroids or IVIg) and it didn't work well enough?
- Have you had at least one platelet count of 50 or higher in response to a past ITP treatment (like prednisone, IVIg, etc.) in the last three years?
En quoi consiste la participation ?
If you decide to take part, you'll first have a screening period of up to two weeks to make sure the study is right for you. If you qualify, you'll be randomly assigned to one of two groups: either you'll receive efgartigimod, or you'll receive a placebo (a dummy medicine). You won't know which one you're getting, and neither will your study doctor, during this 'double-blind' period, which lasts up to 24 weeks.
After this initial phase, everyone will then receive efgartigimod for about 52 weeks. If you and your doctor agree, you might continue receiving efgartigimod for another 52 weeks. Throughout the study, you'll have regular visits to the clinic for check-ups, blood tests, and to receive your study medication, which will be given as an IV (into a vein). After all the treatment periods, there will be a follow-up period of about eight weeks where you won't be taking the study drug. The total time you'd be involved in the study could be up to 138 weeks (roughly 2.5 years).
Risques et avantages potentiels
Locations (94)
- Mayo Clinic Hospital ScottsdaleCode postal vérifiéPhoenix, États-Unis· Recrutement
- University of Southern California Norris Comprehensive Cancer CenterCode postal vérifiéLos Angeles, États-Unis· Recrutement
- Sharp Memorial HospitalCode postal vérifiéOceanside, United States· Recrutement
- University of Colorado HospitalCode postal vérifiéAurora, États-Unis· Recrutement
- Yale University School of MedicineCode postal vérifiéNew Haven, États-Unis· Recrutement
- Georgetown University HospitalCode postal vérifiéWashington D.C., États-Unis· Recrutement
- The University of Chicago MedicineCode postal vérifiéChicago, États-Unis· Recrutement
- The University of Iowa Hospitals & ClinicsCode postal vérifiéIowa City, États-Unis· Recrutement
- Tulane UniversityCode postal vérifiéNouvelle-Orléans, États-Unis· Recrutement
- Henry Ford HealthCode postal vérifiéDetroit, United States· Recrutement
- University of MinnesotaCode postal vérifiéMinneapolis, États-Unis· Recrutement
- Regional Cancer Care Associates, LLC (RCCA)Code postal vérifiéLittle Silver, United States· Recrutement
Questions fréquentes
What is primary immune thrombocytopenia (ITP)?
ITP is a blood disorder where your immune system attacks and destroys your own platelets, which are essential for blood clotting. This can lead to easy bruising or bleeding.
What is efgartigimod?
Efgartigimod is the new experimental medicine being tested in this study to see if it can help increase platelet counts in people with ITP.
Qu'est-ce qu'un 'placebo' ?
A placebo is a treatment that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers understand the true effect of the active medication.
Comment le médicament sera-t-il administré ?
The study medicine, efgartigimod (or the placebo), will be given as an intravenous (IV) infusion, meaning it will be delivered directly into a vein.
Combien de temps vais-je participer à l'étude ?
The study could last for up to 138 weeks, which is about two and a half years, including treatment and follow-up periods.
Comment en savoir plus
Sabine Coppieters, MD
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.